An open label Phase II study to evaluate safety and efficacy of TLX66 in children with high-risk leukemia
Latest Information Update: 21 Aug 2021
At a glance
- Drugs TLX 66 (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Telix Pharmaceuticals
- 21 Aug 2021 New trial record
- 17 Aug 2021 According to Telix Pharmaceuticals media release, the London-based Great Ormond Street Hospital (GOSH) has received UK research ethics approval to commence this trial